IPSEN (OTCMKTS:IPSEY) Sees Significant Growth in Short Interest

IPSEN (OTCMKTS:IPSEY) saw a large growth in short interest in the month of June. As of June 15th, there was short interest totaling 143 shares, a growth of 286.5% from the May 31st total of 37 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 568 shares, the short-interest ratio is currently 0.3 days.

Analysts Set New Price Targets

Several analysts recently commented on IPSEY shares. Zacks Research upgraded shares of IPSEN to a “hold” rating in a report on Friday, May 29th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Finally, HC Wainwright initiated coverage on shares of IPSEN in a research note on Friday, June 5th. They set a “buy” rating for the company. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, IPSEN presently has a consensus rating of “Hold”.

IPSEN Price Performance

IPSEY stock remained flat at $46.50 during mid-day trading on Friday. The company’s stock had a trading volume of 42 shares, compared to its average volume of 578. IPSEN has a 12 month low of $29.05 and a 12 month high of $51.10. The business’s fifty day moving average price is $47.34 and its two-hundred day moving average price is $43.66.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).